Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 6 studies | 20% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 1567.25 | 577 / 578 | 82% | 14.92 | 952 / 1155 |
stomach | 78% | 241.76 | 280 / 359 | 60% | 12.41 | 171 / 286 |
breast | 73% | 182.95 | 335 / 459 | 62% | 11.53 | 698 / 1118 |
uterus | 59% | 112.54 | 100 / 170 | 64% | 21.00 | 295 / 459 |
intestine | 67% | 419.50 | 649 / 966 | 49% | 5.98 | 259 / 527 |
bladder | 67% | 174.05 | 14 / 21 | 49% | 11.84 | 249 / 504 |
esophagus | 47% | 134.59 | 672 / 1445 | 64% | 13.85 | 118 / 183 |
thymus | 81% | 323.27 | 526 / 653 | 30% | 3.06 | 183 / 605 |
kidney | 53% | 201.13 | 47 / 89 | 54% | 8.67 | 488 / 901 |
liver | 81% | 184.24 | 184 / 226 | 25% | 4.19 | 101 / 406 |
ovary | 47% | 103.76 | 85 / 180 | 57% | 5.51 | 243 / 430 |
spleen | 100% | 3009.98 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 3123.94 | 926 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 64.69 | 27 / 29 |
adipose | 93% | 376.18 | 1116 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 89% | 33.87 | 40 / 45 |
prostate | 72% | 218.02 | 176 / 245 | 15% | 0.96 | 74 / 502 |
skin | 22% | 39.14 | 389 / 1809 | 61% | 15.00 | 288 / 472 |
adrenal gland | 63% | 127.71 | 162 / 258 | 6% | 0.38 | 13 / 230 |
pancreas | 11% | 16.19 | 35 / 328 | 47% | 5.34 | 84 / 178 |
blood vessel | 49% | 149.00 | 655 / 1335 | 0% | 0 | 0 / 0 |
heart | 25% | 45.23 | 214 / 861 | 0% | 0 | 0 / 0 |
brain | 9% | 29.13 | 227 / 2642 | 12% | 1.10 | 87 / 705 |
eye | 0% | 0 | 0 / 0 | 14% | 1.57 | 11 / 80 |
muscle | 5% | 7.43 | 44 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0051715 | Biological process | cytolysis in another organism |
GO_0140639 | Biological process | positive regulation of pyroptotic inflammatory response |
GO_0006954 | Biological process | inflammatory response |
GO_0140973 | Biological process | positive regulation of AIM2 inflammasome complex assembly |
GO_0051607 | Biological process | defense response to virus |
GO_0006605 | Biological process | protein targeting |
GO_1900017 | Biological process | positive regulation of cytokine production involved in inflammatory response |
GO_0045089 | Biological process | positive regulation of innate immune response |
GO_0034067 | Biological process | protein localization to Golgi apparatus |
GO_0032731 | Biological process | positive regulation of interleukin-1 beta production |
GO_1900227 | Biological process | positive regulation of NLRP3 inflammasome complex assembly |
GO_0032741 | Biological process | positive regulation of interleukin-18 production |
GO_0042742 | Biological process | defense response to bacterium |
GO_0002218 | Biological process | activation of innate immune response |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0071346 | Biological process | cellular response to type II interferon |
GO_0051289 | Biological process | protein homotetramerization |
GO_0031410 | Cellular component | cytoplasmic vesicle |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0016020 | Cellular component | membrane |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0106139 | Cellular component | symbiont cell surface |
GO_0098552 | Cellular component | side of membrane |
GO_0030659 | Cellular component | cytoplasmic vesicle membrane |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0004866 | Molecular function | endopeptidase inhibitor activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0005525 | Molecular function | GTP binding |
GO_0005515 | Molecular function | protein binding |
GO_0140678 | Molecular function | molecular function inhibitor activity |
GO_0003924 | Molecular function | GTPase activity |
Gene name | GBP5 |
Protein name | Guanylate binding protein 5 Guanylate-binding protein 5 (EC 3.6.5.-) (GBP-TA antigen) (GTP-binding protein 5) (GBP-5) (Guanine nucleotide-binding protein 5) |
Synonyms | UNQ2427/PRO4987 |
Description | FUNCTION: Interferon (IFN)-inducible GTPase that plays important roles in innate immunity against a diverse range of bacterial, viral and protozoan pathogens (By similarity). Hydrolyzes GTP, but in contrast to other family members, does not produce GMP . Following infection, recruited to the pathogen-containing vacuoles or vacuole-escaped bacteria and acts as a positive regulator of inflammasome assembly by promoting the release of inflammasome ligands from bacteria (By similarity). Acts by promoting lysis of pathogen-containing vacuoles, releasing pathogens into the cytosol (By similarity). Following pathogen release in the cytosol, promotes recruitment of proteins that mediate bacterial cytolysis: this liberates ligands that are detected by inflammasomes, such as lipopolysaccharide (LPS) that activates the non-canonical CASP4/CASP11 inflammasome or double-stranded DNA (dsDNA) that activates the AIM2 inflammasome (By similarity). As an activator of NLRP3 inflammasome assembly: promotes selective NLRP3 inflammasome assembly in response to microbial and soluble, but not crystalline, agents . Independently of its GTPase activity, acts as an inhibitor of various viruses infectivity, such as HIV-1, Zika and influenza A viruses, by inhibiting FURIN-mediated maturation of viral envelope proteins . .; FUNCTION: Antigenic tumor-specific truncated splice form. . |
Accessions | ENST00000443807.1 ENST00000370459.8 [Q96PP8-1] E7ETN8 Q96PP8 |